Table 1 Characteristics of bronchiectasis patients.

From: Maximal mid-expiratory flow is a surrogate marker of lung clearance index for assessment of adults with bronchiectasis

Parameter

Study 1 (n = 110)

Study 2 (n = 22) *

Anthropometry

 Age (years)

44.6 ± 14.1

43.1 ± 14.0

 Females (No., %)

67 (60.9%)

14 (63.6%)

 BMI (kg/m2)

20.1 (5.2)

19.2 ± 2.6

 Never-smokers (No., %)

101 (91.8%)

21 (95.5%)

History

 Duration of symptoms (yrs)

12.0 (14.0)

12.5 (9.2)

 No. of exacerbations within 2 yrs

3.0 (3.0)

3.0 (3.0)

HRCT findings

 No. of bronchiectatic lobes

4.0 (4.0)

4.5 (2.2)

 HRCT total score

8.0 (7.0)

8.0 (4.2)

Disease severity

 Bronchiectasis Severity Index

6.0 (5.0)

7.5 (7.3)

Sputum bacteriology when clinically stable

 Pseudomonas aeruginosa (No., %)

39 (35.5%)

9 (40.9%)

 Haemophilus influenzae (No., %)

10 (9.9%)

2 (9.9%)

 Other pathogenic bacteria (No., %) **

25 (22.7%)

4 (18.2%)

Commensals (No., %)

36 (32.7%)

7 (31.8%)

Medications ever used within 6 months #

 Inhaled corticosteroids (No., %)

26 (23.6%)

3 (13.6%)

 Mucolytics (No., %)

83 (75.5%)

19 (86.4%)

 Macrolides (No., %)

41 (37.3%)

6 (27.3%)

Underlying causes ##

 Post-infectious (No., %)

34 (30.9%)

8 (36.4%)

 Immunodeficiency (No., %)

17 (15.5%)

2 (9.9%)

 Miscellaneous known findings (No., %)

16 (14.5%)

3 (13.6%)

 Idiopathic (No., %)

47 (42.7%)

10 (45.5%)

  1. Numerical data were presented as either mean ± standard deviation (SD) or median (interquartile range, IQR) as appropriate. NA: not applicable.
  2. None of the patients was regularly using inhaled, oral or systemic antibiotics.
  3. *The number of patient-reported exacerbation events that did not meet our criteria was not recorded and therefore we could not perform sensitivity analysis on this subgroup.
  4. **Other pathogenic bacteria for the clinically stable cohort included Haemophilus parainfluenzae (n = 8, 7.3%), Escherichia coli (n = 5, 4.5%), Klebsiella pneumoniae (n = 4, 3.6%), Serratia marcescens (n = 2, 1.8%), Streptococcus pneumoniae (n = 1, 0.9%), Moraxella catarrhalis (n = 1, 0.9%), Achromobacter xylosoxidans (n = 1, 0.9%), Proteus mirabilis (n = 1, 0.9%), Haemophilus haemolyticus (n = 1, 0.9%) and Bordetella bronchiseptica (n = 1, 0.9%). The underlying causes of bronchiectasis were determined after meticulous testing recommended by British Thoracic Society guidelines and group discussion (W.J.G., J.J.Y. and Y.H.G.). Further details will be published elsewhere.
  5. #Most patients had ever used more than one category of medications within the last 6 months.
  6. ##Dual underlying causes were determined in a minority of patients, thus the cumulative percentage was greater than 100%. Miscellaneous causes consisted of allergic bronchopulmonary aspergillosis, gastroesophageal reflux disease, asthma, diffuse panbronchiolitis, Kartagener syndrome, non-tuberculous mycobacteria disease, Young’s syndrome, rheumatoid arthritis, lung sequestration syndrome, and lung malformation.
Back to article page